Pfizer preps Viagra copy for New Zealand; Goldman boosts Merck share target to $40;

@FiercePharma: Teva snaps up 57% of Japan's Taiyo for $460M. News | Follow @FiercePharma

> Mylan said it is now selling a generic version of Xibrom eye drops, which were discontinued in February by their original maker, ISTA Pharmaceuticals. News

> The New Zealand patent for Viagra expires in June, opening the field for generic rivals, but Pfizer will be first off the block with its own copy, Avigra, which will sell at half the branded price. Story

> Goldman Sachs increased its EPS estimates for Merck through 2015, as its new hepatitis treatment is expected to add to the company's bottom line, and set a new $40 price target. Report

> Lonza has pushed further into the high-potency active pharmaceutical ingredient sector with another round of investment at its manufacturing facilities in Visp, Switzerland. Article

> Work towards manufacturing scale-up of a smallpox antiviral has been suspended after a protest was filed against award of the U.S. government contract. News

> Primary packaging maker Schott has joined the growing list of drug industry companies seeking to tap Russian government demand for increased domestic manufacturing. Story

> Joe Shields, who leveraged a successful career in product marketing into a broader role as Pfizer's director of worldwide innovation, is leaving later this month for medical device firm LifeScan. Report

Biotech News

 @FierceBiotech:  Analysis: Big Pharma is backing out of more biotech deals. Story | Follow @FierceBiotech

 @JohnCFierce: Amylin sues Lilly over Boehringer pact. Says Lilly is mine and only mine when it comes to treating diabetes. Report | Follow @JohnCFierce

> SciFluor banks $5M for new drug technology. Item 

> Pfizer cancer drug takes big step toward fateful FDA decision. News 

> Biotechs pick up slack in antibiotics development. Article 

> Booming Alexion blueprints new space for fast-growing staff. Report 

Biotech Research News

> Two research groups link DNA region to major depression. Story 

> Report: Human Genome Project was a worthy investment. Item 

> Researchers find genetic clue to causes of birth defects. News 

> Diabetes, obesity, and one 'master switch' to rule them all. Article 

> Pomp and contamination at commencement? Report

Manufacturing News

> Specialty drugs come to Big Pharma's rescue. News

> Pfizer exec: Pharma needs "simplistic flexibility" to manage costs. Report

> Solve the track/trace puzzle with quality control. Story

> PwC reports high pay, attrition at Indian pharmas. News

> Recall and pharma-return service providers join forces. Item

And Finally... Haiti, which had difficulties vaccinating its children even before the 2010 earthquake, has come up with a plan to immunize 90 percent of its newborns by 2015. Piece

Suggested Articles

German viral vector CDMO Vibalogics has hired Lonza veteran Tom Hochuli as global CEO to help lead its U.S. expansion efforts.

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.